Literature DB >> 21319223

Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation.

Xianwu Li1, Eiron Cudaback, C Dirk Keene, Richard M Breyer, Thomas J Montine.   

Abstract

Activation of innate immunity via toll-like receptors (TLRs) is associated with neurodegenerative diseases, and some effectors, like tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6), directly contribute to neurodegeneration. We tested the hypothesis that prostaglandin (PG) E(2) receptor subtype 1 (EP1) was necessary for the induction of microglial cytokines following the activation of innate immunity. Primary murine microglia had cytokine secretion by activators of TLR3 > TLR9 > TLR4 > TLR2. TLR3 activation induced early expression of cyclooxygenase 2 (COX2) and delayed expression of membranous PGE synthase and secretion of PGE(2) . Nonselective and COX2-selective inhibitors blocked TLR3 induction of TNFα and IL-6. Moreover, of the nine of twenty cytokines and chemokines induced by TLR3 activation, only TNFα and IL-6 were significantly dependent on EP1 signaling as determined using microglia from mice homozygous deficient for EP1 gene or wild-type microglia coincubated with an EP1 antagonist. These results were confirmed by blocking intracellular Ca(2+) release with 2-aminoethoxy-diphenyl borate or Xestospongin C, inhibitors of IP3 receptors. Our results show that suppression of microglial EP1 signaling achieves much of the desired effect of COX inhibitors by selectively blocking TLR3-induced microglial secretion of two major effectors of paracrine neuron damage. In combination with the ability of EP1 suppression to ameliorate excitotoxicity, these data point to blockade of EP1 as an attractive candidate therapeutic for neurodegenerative diseases.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21319223      PMCID: PMC3082133          DOI: 10.1002/glia.21125

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  75 in total

1.  Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.

Authors:  Melissa K McCoy; Terina N Martinez; Kelly A Ruhn; David E Szymkowski; Christine G Smith; Barry R Botterman; Keith E Tansey; Malú G Tansey
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

2.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration.

Authors:  Liya Qin; Xuefei Wu; Michelle L Block; Yuxin Liu; George R Breese; Jau-Shyong Hong; Darin J Knapp; Fulton T Crews
Journal:  Glia       Date:  2007-04-01       Impact factor: 7.452

3.  Trial of celecoxib in amyotrophic lateral sclerosis.

Authors:  Merit E Cudkowicz; Jeremy M Shefner; David A Schoenfeld; Hui Zhang; Katrin I Andreasson; Jeffrey D Rothstein; Daniel B Drachman
Journal:  Ann Neurol       Date:  2006-07       Impact factor: 10.422

4.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

Authors:  G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

5.  Elevated CSF prostaglandin E2 levels in patients with probable AD.

Authors:  T J Montine; K R Sidell; B C Crews; W R Markesbery; L J Marnett; L J Roberts; J D Morrow
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

Review 6.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms.

Authors:  Michelle L Block; Luigi Zecca; Jau-Shyong Hong
Journal:  Nat Rev Neurosci       Date:  2007-01       Impact factor: 34.870

7.  Alpha-synuclein expression modulates microglial activation phenotype.

Authors:  Susan A Austin; Angela M Floden; Eric J Murphy; Colin K Combs
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

8.  Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology.

Authors:  G Mehlhorn; M Hollborn; R Schliebs
Journal:  Int J Dev Neurosci       Date:  2000 Jul-Aug       Impact factor: 2.457

9.  Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation.

Authors:  Alicia A Babcock; Martin Wirenfeldt; Thomas Holm; Helle H Nielsen; Lasse Dissing-Olesen; Henrik Toft-Hansen; Jason M Millward; Regine Landmann; Serge Rivest; Bente Finsen; Trevor Owens
Journal:  J Neurosci       Date:  2006-12-06       Impact factor: 6.167

10.  Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein.

Authors:  Jinghua Jin; Feng-Shiun Shie; Jun Liu; Yan Wang; Jeanne Davis; Aimee M Schantz; Kathleen S Montine; Thomas J Montine; Jing Zhang
Journal:  J Neuroinflammation       Date:  2007-01-04       Impact factor: 8.322

View more
  12 in total

1.  Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium.

Authors:  Junyan Zhu; Doris Mayr; Christina Kuhn; Sven Mahner; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Histochem Cell Biol       Date:  2017-11-13       Impact factor: 4.304

2.  Upregulated TLR3 Promotes Neuropathic Pain by Regulating Autophagy in Rat With L5 Spinal Nerve Ligation Model.

Authors:  Weijia Chen; Zhijun Lu
Journal:  Neurochem Res       Date:  2016-12-21       Impact factor: 3.996

3.  APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease.

Authors:  Yue Yang; Eiron Cudaback; Nikolas L Jorstad; Jake F Hemingway; Catherine E Hagan; Erica J Melief; Xianwu Li; Tom Yoo; Shawn B Khademi; Kathleen S Montine; Thomas J Montine; C Dirk Keene
Journal:  Am J Pathol       Date:  2013-07-04       Impact factor: 4.307

4.  Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Aβ42 phagocytosis.

Authors:  Xianwu Li; Erica Melief; Nadia Postupna; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  Am J Pathol       Date:  2014-11-15       Impact factor: 4.307

Review 5.  Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid β neurotoxicity in vitro.

Authors:  Xianwu Li; Shannon E Rose; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-21       Impact factor: 4.147

Review 6.  Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.

Authors:  C Dirk Keene; Eiron Cudaback; Xianwu Li; Kathleen S Montine; Thomas J Montine
Journal:  Curr Opin Neurobiol       Date:  2011-09-08       Impact factor: 6.627

7.  Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia.

Authors:  Xianwu Li; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  FASEB J       Date:  2015-01-15       Impact factor: 5.191

8.  Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor.

Authors:  Xianwu Li; Eiron Cudaback; Richard M Breyer; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  FASEB J       Date:  2012-04-12       Impact factor: 5.191

9.  Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice.

Authors:  Yue Yang; Macarena S Aloi; Eiron Cudaback; Samuel R Josephsen; Samantha J Rice; Nikolas L Jorstad; C Dirk Keene; Thomas J Montine
Journal:  Lab Invest       Date:  2014-09-08       Impact factor: 5.662

10.  Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation.

Authors:  Eiron Cudaback; Xianwu Li; Yue Yang; Thomas Yoo; Kathleen S Montine; Suzanne Craft; Thomas J Montine; Christopher Dirk Keene
Journal:  J Neuroinflammation       Date:  2012-08-10       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.